SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice

Despite the rapid development and approval of several COVID vaccines based on the full-length spike protein, there is a need for safe, potent, and high-volume vaccines. Considering the predominance of the production of neutralizing antibodies targeting the receptor-binding domain (RBD) of S-protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Volosnikova, Ekaterina A., Merkuleva, Iuliia A., Esina, Tatiana I., Shcherbakov, Dmitry N., Borgoyakova, Mariya B., Isaeva, Anastasiya A., Nesmeyanova, Valentina S., Volkova, Natalia V., Belenkaya, Svetlana V., Zaykovskaya, Anna V., Pyankov, Oleg V., Starostina, Ekaterina V., Zadorozhny, Alexey M., Zaitsev, Boris N., Karpenko, Larisa I., Ilyichev, Alexander A., Danilenko, Elena D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146165/
https://www.ncbi.nlm.nih.gov/pubmed/37112720
http://dx.doi.org/10.3390/vaccines11040808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146165/
https://www.ncbi.nlm.nih.gov/pubmed/37112720
http://dx.doi.org/10.3390/vaccines11040808

Ejemplares similares